Stock ASMB ASSEMBLY BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Assembly Biosciences, Inc.

Equities

ASMB

US0453962070

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
12.65 USD -5.31% Intraday chart for Assembly Biosciences, Inc. -5.67% +28.54%
Mar. 28 Assembly Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jan. 19 Assembly Biosciences Insider Bought Shares Worth $511,264, According to a Recent SEC Filing MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
AQ
Assembly Biosciences Announces Effective Date of Reverse Stock Split
GL
Assembly Biosciences Announces Effective Date of Reverse Stock Split
AQ
Assembly Biosciences Provides Anticipated Development Milestones for 2024
GL
Assembly Biosciences Provides Anticipated Development Milestones for 2024
AQ
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®
GL
Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®
AQ
Assembly Biosciences: Q3 Earnings Snapshot
AQ
Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates
GL
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
GL
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
AQ
Nano-Cap Stock Momentum Watchlist (SING, MGRX, ICU, ASMB)
AQ
Assembly Biosciences : 737.6 KB
PU
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
GL
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
AQ
Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
GL
Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
AQ
Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ASMB Stock
  4. News Assembly Biosciences, Inc.
  5. Press Releases